文献速递胸部神经CT

基于CT影像组学与临床病理因素列线图识别适合三代EGFR-TKI联合胸部放疗的EGFR突变寡转移性非小细胞肺癌患者

Identifying Patients with EGFR-Mutated Oligometastatic NSCLC Suitable for Third-Generation EGFR-TKI Combined with Thoracic Radiotherapy Using Nomograms Based on CT Radiomic and Clinicopathological Factors.
PubMed 文献 · Acad Radiol · 2025-11-24

纳入338例一线接受三代EGFR-TKI治疗的EGFR突变寡转移性NSCLC患者,分训练与验证队列,结合临床病理变量与影像组学特征构建列线图预测PFS与OS。训练队列1/2/3年PFS的AUC为0.858/0.834/0.785,验证队列为0.800/0.740/0.734;模型可分层低危与高危,高危患者从胸部放疗获得显著PFS与OS获益,低危患者未见显著获益。

要点

  • 影像组学评分(Rad-score)是PFS与OS的独立预测因素,纳入列线图。
  • 高危组联合胸部放疗PFS与OS获益显著(p<0.001),低危组未见显著获益。
  • 列线图训练队列1/2/3年PFS的AUC为0.858/0.834/0.785。

核心结论

  • 整合临床病理与影像组学因素的列线图可对一线三代EGFR-TKI治疗的EGFR突变寡转移性NSCLC患者进行风险分层,帮助判断哪些患者从联合胸部放疗中获益最大、低危患者避免不必要的胸部放疗。

研究设计与样本

  • 共纳入338例接受一线三代EGFR-TKI治疗的EGFR突变寡转移性NSCLC患者,分为训练队列与验证队列;采用单因素与多因素分析筛选PFS和OS的独立预后因素并构建列线图,以ROC曲线、校准曲线和决策曲线分析进行验证。

诊断标准与关键数值

  • PFS独立危险因素:EGFR外显子21 L858R突变、脑转移、中性粒细胞与淋巴细胞比值≥4.39及影像组学评分(Rad-score)。
  • OS独立预测因素:年龄>60岁、EGFR外显子21 L858R突变、脑转移、单核细胞与淋巴细胞比值>0.26及Rad-score。
  • 训练队列列线图1、2、3年PFS的AUC分别为0.858、0.834、0.785,2、3、4年OS的AUC分别为0.882、0.868、0.877。
  • 验证队列1、2、3年PFS的AUC分别为0.800、0.740、0.734,2、3、4年OS的AUC分别为0.835、0.729、0.766。
  • 高危患者接受胸部放疗的PFS(p<0.001)与OS(p<0.001)获益显著,低危患者PFS(p=0.056)与OS(p=0.093)未见显著改善。

临床应用与阅片要点

  • 阅片时可依据列线图整合的临床病理因素与影像组学评分对患者进行低危与高危分层。
  • 高危患者联合胸部放疗PFS与OS获益显著(p<0.001),低危患者未见显著获益(PFS p=0.056,OS p=0.093)。
  • 作者认为该列线图有助于判断哪些患者从联合胸部放疗中获益最大,并帮助低危患者避免不必要的胸部放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: It remains uncertain whether all patients with oligometastatic non-small cell lung cancer (NSCLC) benefit from the combination of third-generation EGFR-TKIs and TRT. This study aimed to identify which patients are most likely to benefit from combined third-generation EGFR-TKI and TRT, and which patients may safely omit TRT, thereby guiding clinical decision-making and optimizing prognosis.

MATERIALS AND METHODS: A total of 338 patients with EGFR-mutated oligometastatic NSCLC who received first-line third-generation EGFR-TKI treatment were included. These patients were divided into training and validation cohorts. Univariate and multivariate analyses incorporating clinicopathological variables and radiomic features were performed to identify independent prognostic factors for progression-free survival (PFS) and overall survival (OS). A predictive nomogram was developed based on these factors and validated using receiver operating characteristic curves, calibration curves, and decision curve analysis.

RESULTS: EGFR exon 21 L858R mutation, brain metastasis, neutrophil-to-lymphocyte ratio ≥ 4.39, and the radiomic score (Rad-score) were identified as independent risk factors for PFS. Age > 60 years, EGFR exon 21 L858R mutation, brain metastasis, monocyte-to-lymphocyte ratio > 0.26, and Rad-score were OS independent predictors. In the training cohort, the nomogram achieved excellent predictive performance with AUCs of 0.858, 0.834, and 0.785 for 1-, 2-, and 3-year PFS, and 0.882, 0.868 and 0.877 for 2-, 3-, and 4-year OS, respectively. In the validation cohort, respective AUCs were 0.800, 0.740, and 0.734,and 0.835, 0.729, 0.766, confirming good discrimination. The model successfully stratified patients into low- and high-risk groups. High-risk patients derived significant PFS (p < 0.001) and OS (p < 0.001) benefits from TRT, whereas low-risk patients did not show significant improvements in PFS (p = 0.056) or OS (p = 0.093) with TRT.

CONCLUSION: We established and confirmed a robust predictive nomogram that integrates clinicopathological and radiomic factors to stratify patients with first-line therapy for EGFR-mutant oligometastatic NSCLC involving third-generation EGFR-TKIs. This approach helps determine which patients may gain the greatest benefit from combined TRT and help avoid unnecessary TRT in low-risk patients, supporting precision treatment strategies.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Gu X, Zhao J, Geng J, et al. Identifying Patients with EGFR-Mutated Oligometastatic NSCLC Suitable for Third-Generation EGFR-TKI Combined with Thoracic Radiotherapy Using Nomograms Based on CT Radiomic and Clinicopathological Factors. Acad Radiol. 2025. PMID: 41290432. doi:10.1016/j.acra.2025.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。